

Please note: the substantive content of the 2026 NRI Roadmap Survey begins at Question 20 (with prior questions dealing with administrative and other information).

As such all submissions that are published include the responses submitted from Question 20 onwards only.

Q20.

Part 2: Research themes

2.1 NRI comprises the assets, facilities and associated expertise to support leading-edge research and innovation in Australia and is accessible to publicly and privately funded users across Australia and internationally. We are seeking your input on possible directions for future national-level investment - i.e., where the requirements are of such scale and importance that national-level collaboration and coordination are essential.

The [2021 Roadmap](#) used a challenge framework to support NRI planning and investment. With this in mind, consider likely future research trends in the next 5 - 10 years, and with respect to one or more of the 8 challenge areas identified in the 2021 Roadmap as listed below:

- describe emerging research directions and the associated critical research infrastructure requirements that are either not currently available at all, or not at sufficient scale and
- describe current national infrastructure requirements that you anticipate will no longer fit the definition of NRI in 5-10 years.

Do not limit your commentary to NCRIS funded capabilities.

Q21.

Resources Technology and Critical Minerals Processing

Q22.

Food and Beverage

Q23.

Medical Products

Genomics is revolutionising the field of human health, from diagnostic and therapeutic products to vaccines and surveillance, and covering chronic diseases, cancer, infectious diseases, neurodegenerative diseases and others. Widespread availability of high-depth genomic sequencing with rapid clinical turnaround times, availability in rural, regional and remote settings is critical to bring the era of individualised medicine to Australians and for us to export our research and implementation science to the region. Currently, there is not nearly enough sequencing capacity to realise the economies of scale and benefits of very large datasets that will transform genomic approaches. Finally, very strong bioinformatics support from flexible high performance computing facilities is required to ensure that the outputs of genomic sequencing can be optimised, employing machine learning approaches. It is important that this capacity is based onshore in Australia to preserve data integrity and confidentiality and is flexible, widely available to researchers in Universities, state and federal health services and in the private sector. Current computing capacity provided by NCI and Pawsey is reasonably strong now, but should be enhanced for human genomic research with dedicated human-genomics-only resources needed to maximise sensitive data security and access in clinically relevant timeframes.

Q24.

Defence

Q25.

Recycling and Clean Energy

Q26.

Space

Q27.

Environment and Climate

Q28.

Frontier Technologies and Modern Manufacturing

Q29.

2.2 The 2024 statement of National Science and Research Priorities (NSRPs) includes outcomes linked to each priority to assist in identifying critical research needed in the next 5 to 10 years.

Consider the priority statements and, with respect to one or more of the 5 priority areas as listed below:

- describe emerging research directions and the associated critical research infrastructure requirements that are either not currently available at all, or
- not at sufficient scale and describe current national infrastructure requirements that you anticipate will no longer fit the definition of NRI in 5-10 years.

Do not limit your commentary to NCRIS funded capabilities, and where relevant, refer to the underpinning outcomes and research identified in the NSRPs document.

Q30.

Transitioning to a net zero future

Q31.

Supporting healthy and thriving communities

Again, genomics is perhaps the most important emerging, large scale technology to ensure this through individualised medicine, enhanced diagnostics and disease surveillance, but current sequencing and bioinformatics capacity is insufficient, unevenly available (especially in regional, rural and remote areas) and not readily accessible to end users.

Q32.

Elevating Aboriginal and Torres Strait Islanders knowledge systems

Q33.

Protecting and restoring Australia’s environment

Q34.

Building a secure and resilient nation

Q35.

2.3 The case for a new NRI capability, or enhancements to existing capabilities, typically emerges through advocacy from research communities clustering around rigorously identified needs and goals. Such a concept could respond to a requirement for novel or expanded capacity within a domain, or across domains, and must be such that it could only be made available with national-level investment.

If you have identified such a requirement, briefly describe the need, the proposed infrastructure capability, the medium-term goals, impacted research communities, and the timeframe over which you advocate its establishment. Your response can include links to relevant existing reports.

I think we need a national genomics infrastructure, comprising wet lab and sequencing capacity at massive scale, backed up with accessible, rapid bioinformatics with the medium-term goal over 10 years of bringing individualised genomic medicine to every Australian who needs it.

Q36.

Part 3: Industry perspectives

This section is seeking input specifically from industry-based respondents. Other respondents can skip this section.

Recommendation 6 of the [2021 Roadmap](#) related to improvements in industry engagement with NRI. To complement work on this topic that has occurred since then, we are seeking additional advice on NRI requirements as perceived by current or potential industry-based users.

Q37.

3.1 Have you (or your organisation) interreacted with or used Australia's NRI?

☒ Yes

☐ No

Q38.

3.2 If so, please briefly outline the NRI capabilities you (or your organisation) have interacted with or used. Do not limit your response to NCRIS capabilities.

NCI and Pawsey

Q39.

3.3 Please indicate your (one or more) primary reasons for interacting with NRI:

- ☒ For expertise or advice
- ☐ Access to research resources or products
- ☒ Access to equipment for research
- ☒ Access to equipment for operational reasons
- ☐ Help in translating research
- ☐ Access to data
- ☐ Support for clinical trials
- ☐ Other (please specify)

Q40.

3.4 If you answered no, please indicate your (one or more) primary reasons:

This question was not displayed to the respondent.

Q41.

Part 4: Other comments

4.1 Please elaborate on any of your above responses or add any other comments relevant to the development of the 2026 Roadmap. Your response can include reference or links to existing reports that you recommend be considered during the 2026 Roadmap development process.

Q49.

4.2 Optional Document Attachment.

Note: Our strong preference is that answers are provided against the relevant questions in the survey. However, this file upload option is available for submissions in file format, where needed. Please ensure the document includes your name or organisation.